Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan Sells 15,000 Shares

Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan sold 15,000 shares of the stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $127.22, for a total transaction of $1,908,300.00. Following the transaction, the director now directly owns 2,284,015 shares of the company’s stock, valued at approximately $290,572,388.30. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Noubar Afeyan also recently made the following trade(s):

• On Tuesday, June 11th, Noubar Afeyan sold 202,832 shares of Moderna stock. The stock was sold at an average price of $148.34, for a total transaction of $30,088,098.88.
• On Wednesday, June 5th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $151.25, for a total transaction of $2,268,750.00.
• On Wednesday, May 29th, Noubar Afeyan sold 20,000 shares of Moderna stock. The stock was sold at an average price of $145.08, for a total transaction of $2,901,600.00.
• On Wednesday, May 22nd, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $157.57, for a total transaction of $2,363,550.00.
• On Wednesday, May 15th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $127.32, for a total transaction of $1,909,800.00.
• On Wednesday, May 8th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $121.68, for a total transaction of $1,825,200.00.
• On Wednesday, May 1st, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $110.92, for a total transaction of $1,663,800.00.
• On Wednesday, April 24th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $108.32, for a total transaction of $1,624,800.00.
• On Wednesday, April 17th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $103.38, for a total transaction of $1,550,700.00.
• On Wednesday, April 10th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $107.12, for a total transaction of $1,606,800.00.

Moderna Price Performance

Shares of Moderna stock opened at $118.75 on Friday. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $170.47. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. The company’s fifty day moving average is $134.13 and its two-hundred day moving average is $111.72.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. During the same period last year, the firm posted $0.19 EPS. Moderna’s revenue for the quarter was down 91.0% on a year-over-year basis. As a group, sell-side analysts forecast that Moderna, Inc. will post -7.46 earnings per share for the current fiscal year.

Institutional Trading of Moderna

Several hedge funds and other institutional investors have recently made changes to their positions in MRNA. LPL Financial LLC boosted its holdings in shares of Moderna by 7.2% in the third quarter. LPL Financial LLC now owns 115,782 shares of the company’s stock valued at $11,959,000 after acquiring an additional 7,811 shares in the last quarter. Mariner LLC boosted its holdings in shares of Moderna by 5.2% in the third quarter. Mariner LLC now owns 20,242 shares of the company’s stock valued at $2,091,000 after acquiring an additional 996 shares in the last quarter. Stifel Financial Corp lifted its stake in shares of Moderna by 19.0% in the third quarter. Stifel Financial Corp now owns 75,871 shares of the company’s stock valued at $7,837,000 after purchasing an additional 12,099 shares during the period. Natixis Advisors L.P. lifted its stake in shares of Moderna by 19.9% in the third quarter. Natixis Advisors L.P. now owns 19,924 shares of the company’s stock valued at $2,058,000 after purchasing an additional 3,310 shares during the period. Finally, O Shaughnessy Asset Management LLC lifted its stake in shares of Moderna by 34.0% in the third quarter. O Shaughnessy Asset Management LLC now owns 7,664 shares of the company’s stock valued at $792,000 after purchasing an additional 1,945 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analyst Ratings Changes

MRNA has been the topic of a number of analyst reports. William Blair restated a “market perform” rating on shares of Moderna in a report on Thursday. Canaccord Genuity Group raised their price objective on shares of Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a report on Friday, May 3rd. Evercore ISI restated an “in-line” rating and issued a $120.00 price objective on shares of Moderna in a report on Thursday. Oppenheimer raised their price objective on shares of Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a report on Wednesday, June 12th. Finally, Piper Sandler restated an “overweight” rating and issued a $214.00 price objective on shares of Moderna in a report on Thursday. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Moderna has an average rating of “Hold” and an average price target of $134.02.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.